Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?

Nature Clinical Practice Oncology

Volumn 3, Issue 1, 2006, Pages 22-23

  Grothey, Axel ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

Bevacizumab; Colorectal cancer; Fluorouracil; Leucovorin; Survival

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ARTERY THROMBOSIS; BLEEDING DISORDER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAZARD ASSESSMENT; HISTOPATHOLOGY; HUMAN; HYPERTENSION; METASTASIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; SHORT SURVEY; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

EID: 30944458460     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0380     Document Type: Short Survey

References (4)

1. Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
2. Hurwitz HI et al. (2005) Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508
3. Kabbinavar F et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65
4. Kabbinavar FF et al. (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23: 3697-3705